Logo image of PROF

PROFOUND MEDICAL CORP (PROF) Stock Fundamental Analysis

USA - NASDAQ:PROF - CA74319B5027 - Common Stock

5.98 USD
+0.11 (+1.87%)
Last: 10/13/2025, 8:00:00 PM
Fundamental Rating

3

Overall PROF gets a fundamental rating of 3 out of 10. We evaluated PROF against 191 industry peers in the Health Care Equipment & Supplies industry. While PROF seems to be doing ok healthwise, there are quite some concerns on its profitability. PROF is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year PROF has reported negative net income.
PROF had a negative operating cash flow in the past year.
In the past 5 years PROF always reported negative net income.
PROF had a negative operating cash flow in each of the past 5 years.
PROF Yearly Net Income VS EBIT VS OCF VS FCFPROF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -82.01%, PROF is doing worse than 73.82% of the companies in the same industry.
The Return On Equity of PROF (-103.75%) is worse than 63.35% of its industry peers.
Industry RankSector Rank
ROA -82.01%
ROE -103.75%
ROIC N/A
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
PROF Yearly ROA, ROE, ROICPROF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of PROF (69.43%) is better than 78.53% of its industry peers.
PROF's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for PROF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
PROF Yearly Profit, Operating, Gross MarginsPROF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

5

2. Health

2.1 Basic Checks

PROF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PROF has been increased compared to 1 year ago.
PROF has more shares outstanding than it did 5 years ago.
PROF has a better debt/assets ratio than last year.
PROF Yearly Shares OutstandingPROF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PROF Yearly Total Debt VS Total AssetsPROF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 1.20, we must say that PROF is in the distress zone and has some risk of bankruptcy.
PROF has a Altman-Z score (1.20) which is in line with its industry peers.
PROF has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PROF (0.12) is better than 62.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 1.2
ROIC/WACCN/A
WACC7.92%
PROF Yearly LT Debt VS Equity VS FCFPROF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

PROF has a Current Ratio of 8.53. This indicates that PROF is financially healthy and has no problem in meeting its short term obligations.
PROF has a Current ratio of 8.53. This is amongst the best in the industry. PROF outperforms 90.05% of its industry peers.
PROF has a Quick Ratio of 7.07. This indicates that PROF is financially healthy and has no problem in meeting its short term obligations.
PROF has a Quick ratio of 7.07. This is amongst the best in the industry. PROF outperforms 89.53% of its industry peers.
Industry RankSector Rank
Current Ratio 8.53
Quick Ratio 7.07
PROF Yearly Current Assets VS Current LiabilitesPROF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

7

3. Growth

3.1 Past

PROF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.67%.
The Revenue has grown by 50.25% in the past year. This is a very strong growth!
PROF shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.67% yearly.
EPS 1Y (TTM)-19.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.71%
Revenue 1Y (TTM)50.25%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%-0.99%

3.2 Future

Based on estimates for the next years, PROF will show a very strong growth in Earnings Per Share. The EPS will grow by 26.32% on average per year.
The Revenue is expected to grow by 74.43% on average over the next years. This is a very strong growth
EPS Next Y-38.2%
EPS Next 2Y-6.49%
EPS Next 3Y2.89%
EPS Next 5Y26.32%
Revenue Next Year51.68%
Revenue Next 2Y83.42%
Revenue Next 3Y73.26%
Revenue Next 5Y74.43%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PROF Yearly Revenue VS EstimatesPROF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
PROF Yearly EPS VS EstimatesPROF Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PROF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PROF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROF Price Earnings VS Forward Price EarningsPROF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PROF Per share dataPROF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.49%
EPS Next 3Y2.89%

0

5. Dividend

5.1 Amount

No dividends for PROF!.
Industry RankSector Rank
Dividend Yield N/A

PROFOUND MEDICAL CORP

NASDAQ:PROF (10/13/2025, 8:00:00 PM)

5.98

+0.11 (+1.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)10-30 2025-10-30/amc
Inst Owners45.81%
Inst Owner Change-0.01%
Ins Owners17.71%
Ins Owner Change3.75%
Market Cap180.12M
Analysts80
Price Target11.09 (85.45%)
Short Float %2.79%
Short Ratio5.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-33.7%
Min EPS beat(2)-40.1%
Max EPS beat(2)-27.3%
EPS beat(4)1
Avg EPS beat(4)-13.29%
Min EPS beat(4)-40.1%
Max EPS beat(4)42.88%
EPS beat(8)4
Avg EPS beat(8)-6.05%
EPS beat(12)7
Avg EPS beat(12)-1.83%
EPS beat(16)9
Avg EPS beat(16)-2.03%
Revenue beat(2)0
Avg Revenue beat(2)-31.94%
Min Revenue beat(2)-38.03%
Max Revenue beat(2)-25.86%
Revenue beat(4)0
Avg Revenue beat(4)-17.41%
Min Revenue beat(4)-38.03%
Max Revenue beat(4)-2.68%
Revenue beat(8)1
Avg Revenue beat(8)-15.76%
Revenue beat(12)1
Avg Revenue beat(12)-19.57%
Revenue beat(16)2
Avg Revenue beat(16)-22.34%
PT rev (1m)-1.79%
PT rev (3m)31.03%
EPS NQ rev (1m)6.29%
EPS NQ rev (3m)-7.45%
EPS NY rev (1m)-3.03%
EPS NY rev (3m)-38.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.21
P/FCF N/A
P/OCF N/A
P/B 4.59
P/tB 4.61
EV/EBITDA N/A
EPS(TTM)-1.46
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0.39
BVpS1.3
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.01%
ROE -103.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.43%
FCFM N/A
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.53
Quick Ratio 7.07
Altman-Z 1.2
F-Score3
WACC7.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.71%
EPS Next Y-38.2%
EPS Next 2Y-6.49%
EPS Next 3Y2.89%
EPS Next 5Y26.32%
Revenue 1Y (TTM)50.25%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%-0.99%
Revenue Next Year51.68%
Revenue Next 2Y83.42%
Revenue Next 3Y73.26%
Revenue Next 5Y74.43%
EBIT growth 1Y-37.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.37%
EBIT Next 3Y6.51%
EBIT Next 5Y30.47%
FCF growth 1Y-48.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.97%
OCF growth 3YN/A
OCF growth 5YN/A